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Abstract 
Head and neck cancer (HNC) IMRT treatment planning is a challenging process 
that relies heavily on the planner’s experience. Previously, we used the single, best 
match from a library of manually planned cases to semi-automatically generate IMRT 
plans for a new patient. The current multi-case Knowledge Based Radiation Therapy 
(MC-KBRT) study utilized different matching cases for each of six individual organs-at-
risk (OARs), then combined those six cases to create the new treatment plan.   
From a database of 103 patient plans created by experienced planners, MC-KBRT 
plans were created for 40 (17 unilateral and 23 bilateral) HNC “query” patients. For each 
case, 2D beam’s-eye-view images were used to find similar geometric “match” patients 
separately for each of 6 OARs. Dose distributions for each OAR from the 6 matching 
cases were combined and then warped to suit the query case’s geometry.  The dose-
volume constraints were used to create the new query treatment plan without the need 
for human decision-making throughout the IMRT optimization.  The optimized MC-
KBRT plans were compared against the clinically approved plans and Version 1 
(previous KBRT using only one matching case with dose warping) using the dose 
metrics: mean, median, and maximum (brainstem and cord+5mm) doses. 
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Compared to Version 1, MC-KBRT had no significant reduction of the dose to 
any of the OARs in either unilateral or bilateral cases.  Compared to the manually 
planned unilateral cases, there was significant reduction of the oral cavity mean/median 
dose (>2Gy) at the expense of the contralateral parotid.  Compared to the manually 
planned bilateral cases, reduction of dose was significant in the ipsilateral parotid, 
larynx, and oral cavity (>3Gy mean/median) while maintaining PTV coverage.   
MC-KBRT planning in head and neck cancer generates IMRT plans with better 
dose sparing than manually created plans. MC-KBRT using multiple case matches does 
not show significant dose reduction compared to using a single match case with dose 
warping. 
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1. Introduction  
1.1 Clinical Relevance 
Head and neck cancer (HNC) incorporates between 3-5% of all cancers 
diagnosed in the United States.  As defined by the National Cancer Institute, head and 
neck cancers include cancer in the nasal cavity, sinuses, nose, lips, mouth, salivary 
glands, throat, or larynx and excludes tumors in the brain, eyes, thyroid gland, skin, 
muscles, and bones [1].  In 2013, according to the American Cancer Society, 55,070 
individuals will be diagnosed with head and neck cancer.  In addition, over 20% of these 
individuals will die from this type of cancer annually.  Early stage diagnosis of head and 
neck cancer has a high cure rate; however, approximately 2/3 of the cases are diagnosed 
in later stages of tumor growth, making treatment difficult.  Treatment of patients with 
this disease includes surgery and radiation therapy.  Occasionally in more advanced 
stages of this cancer, adjuvant chemotherapy is used in order to use all efforts to reduce 
the effects of cancer [2].   
1.2 Head and Neck IMRT Optimization 
Intensity modulated radiation therapy (IMRT) is the preferred external beam 
radiation therapy (EBRT) option for head and neck cancer.  IMRT is intended to target 
the tumor precisely, while sparing the normal tissue including the organs at risk (OARs) 
[3-8].  The target defined in IMRT is the planning target volume (PTV).  The PTV is an 
expansion of the clinical target volume (CTV), which includes the gross tumor volume in 
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addition to a margin for sub-clinical disease spread and an additional margin allowing 
for uncertainties in the treatment delivery or planning [9].   
 
Figure 1: Example of GTV (yellow), CTV (red), and PTV (blue) expansion on 
an axial CT slice for a case of glottis cancer. 
The PTV defined by the physician should ideally receive a uniform 100% of the 
prescribed dose with preferably no area receiving greater than 115% of the prescription 
dose.   
In addition to delivering the prescription dose to the PTV, dose to the normal 
tissue and OARs must be minimized.  The OARs that are prevalent in head and neck 
cancer include the larynx, left and right parotids, spinal cord, brainstem, and oral cavity. 
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Figure 2: OARs spared in HNC treatment plans. Generated with Eclipse 
treatment planning software 
At Duke University, a standard margin of 5mm is added to the spinal cord to 
create a planning risk volume that incorporates possible errors in motion and patient 
positioning.  Mandible is not included in the study due to its recent incorporation in the 
planning process.  Radiation damage to any of these OARs could have life-impairing 
effects on the patient including sensory disturbances, motor function anomalies, 
cognitive impairments, regulatory problems, xerostomia, mucositis, sleepiness, etc.  
HNC is considered to be the most challenging disease site in radiation therapy due to 
the complex juxtaposition and overlap between PTV and OARs. With an IMRT plan, the 
dose to the OARs is ideally zero, but since that is not practically possible, instead the 
goal is to keep doses below certain limits.  For this research, limits are reflected by the 
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standards used in the Duke clinic.  For the parotid glands and larynx, an upper limit of 
24 Gy median dose is desirable, the oral cavity has a limit of 30 Gy median dose, the 
brainstem has an upper limit of 20 Gy maximum dose, and the spinal cord+5mm has a 
limit of 45 Gy maximum dose.  Patient responses to radiation are variable, so these limits 
are guidelines to create a quality plan [10].   
The IMRT optimization process involves the minimization of an objective 
function.  The total objective function includes meeting the constraints and priorities 
specified by the dosimetrist for both the PTV and all of the OARs.  Once this objective 
function is minimized, the fluence intensity map within each beam is altered throughout 
the treatment.   
When compared to 3D conformal treatment planning, IMRT shows superior 
sparing of the OARs and reduced risk of complications, but may not cover the target as 
homogeneously [11, 12].  A study was performed to analyze the stimulated parotid 
saliva (SPS) flow at 12 months after radiation therapy compared to before treatment.  
These patients’ SPS flow returned to at least 25% of its initial function in 83.3% of 
patients receiving IMRT compared to only 9.5% of patients receiving conventional 
radiation therapy.  Patients receiving IMRT had notably better parotid sparing and 
improved quality of life [13]. 
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1.3 KBRT Treatment Planning Background 
IMRT plans are usually created by optimizing the doses in a trial-and-error 
fashion.  In the clinic, head-and-neck cancer (HNC) IMRT treatment planning relies 
heavily on the planner’s experience in achieving the best dose sparing to OARs and 
generally takes a considerable amount of time [14, 15].  More experienced planners have 
been shown to produce superior IMRT plans [16]. 
Research has been done toward creating high quality IMRT treatment plans for a 
new “query” patient by adapting the parameters from previously planned “match” 
patients who are anatomically similar to the new patient.  Prior work has been done 
from other groups in data-driven IMRT treatment planning including one study that 
used an overlap volume histogram instead of looking at the geometric overlap [17].  
Looking particularly at other research in prostate treatment planning, “machine 
learning” was applied to develop new plans using the organ volumes and a distance-to-
target histogram [18].  Another study of pancreatic adenocarcinoma used a shape-based 
treatment planning method to predict the dose received based on the OAR orientation 
and distance to the PTV [19].   
Within our group, a prostate study was performed using the same mutual 
information technique that is still currently used.  Unlike with HNC where dose 
warping is used, optimization parameters were simply taken from the match case [15].  
The overlap of the PTV with OARs can be measured by the closeness of the beams-eye-
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view (BEV) projection images of the target volume and the OARs.  This gives a 
similarity metric between the “query” and “match cases” [15, 20].  In previous 
knowledge-based work, it was assumed that the manually planned patients most 
geometrically similar to a new patient will have treatment plans that can be easily 
adapted to the new “query” patient.  Within our group, similar dose-volume histograms 
(DVHs) for a new patient were achieved by using the OAR dose-volume constraints 
extracted from the DVH of previously planned similar cases to guide the IMRT planning 
optimization process for both prostate and HNC cases [15, 21].  The premise behind this 
knowledge-based method is to produce high quality plans at a fraction of the time when 
creating de novo plans. 
Head-and-neck treatment plans show larger deviations from the prescribed 
doses compared to brain and prostate cancer plans [22].  The PTVs of HNC patients vary 
significantly from one another in both size and shape between patients.  Due to irregular 
shapes of the targets and suboptimal HNC plans in the database, the methodology that 
our group used to generate prostate plans needed to be revised.  The revised 
methodology for knowledge-based radiation therapy (KBRT) IMRT treatment planning 
for HNC has been performed by warping the dose distribution from the single most 
similar patient to suit the PTV/OAR geometry of the new patient.  This warped dose 
distribution was used to generate dose-volume constraints for the new patient, and this 
previous approach will be referred to as Version 1 (V1) [21]. 
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This work aims to semi-automatically generate IMRT treatment plans, based on 
the individual OARs, that are of the same quality as plans produced by both 
experienced human planners and prior automated work.  Most importantly, this is the 
first study that incorporates data from multiple matching plans, each of which 
represents the best overlap of the PTV with individual OARs. This multi-case KBRT 
approach is compared against not only the original, clinically treated plan, but also the 
V1 approach that is based on only the single, best matching case. 
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2. Methods and Materials 
2.1 Knowledge Database 
The knowledge database used in this research included clinical IMRT treatment 
plans from 103 head and neck cancer patients treated at Duke University Health System 
between 2009 and 2012.  The clinical cases chosen included the primary and boost plans, 
which consisted of between 6 and 9 coplanar 6 MV beams.  Beam angles were either 
distributed equally for bilateral cases or focused around the target side for unilateral 
cases.  The OARs considered for this dose-sparing study included the larynx, parotid 
glands, oral cavity, brainstem, and spinal cord +5 mm expansion.   
The clinical plans were optimized manually to meet the planning constraints set 
by the radiation oncologist.  In general, these clinical constraints were set at < 24 Gy 
median dose for the parotid glands, oral cavity, and larynx, < 25 Gy for the maximum 
dose to the brainstem, and < 45 Gy maximum dose to the spinal cord +5 mm.  In 
particularly difficult individual cases, the constraints were either relaxed or tightened 
depending on the overlap of the OARs and the target [10]. 
Twenty-three bilateral and seventeen unilateral patients were chosen randomly 
as query patients for whom new multi-case knowledge-based IMRT (MC-KBRT) 
treatment plans were to be created.  The unilateral cases were comprised of 1 left parotid 
gland cancer, 1 right parotid gland cancer, 1 oral tongue cancer, 1 recurring sinus cancer, 
1 lymph node cancer, 1 bone marrow cancer, 5 left tonsil cancers, and 6 right tonsil 
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cancer cases (See Appendix for prescription doses); bilateral cases were comprised of 1 
glottis cancer, 1 supraglottis cancer, 1 lip cancer, 1 oropharyngeal cancer, 1 right tonsil 
cancer, 1 left tonsil cancer, 2 nasopharyngeal cancers, 6 lymph node cancers, and 9 base 
of tongue cancers (See Appendix for prescription doses).    Prescription doses for all of 
these patients varied from 60 to 70 Gy.  For each query case in question, the remaining 
102 cases in the knowledge base served as potential match cases.  These potential match 
cases were used to guide the query MC-KBRT plan.  The MC-KBRT plans generated 
were compared dosimetrically to both the original clinical plans used to treat the 
patients and Version 1. 
2.2 Match Case Selection 
The query patient’s anatomical structures were converted into 2D Beam’s Eye 
View (BEV) projections of the standard 9 angles.  These query BEV’s were compared to 
the database using a summation of the mutual information (MI) values at each angle to 
find the closest anatomical/geometric “match” for each OAR.  For each query OAR, 
IMRT optimization constraints were adapted from the closest match case.  These 
constraints were imported into the Eclipse Treatment Planning System (version 10.0.28, 
Varian Medical Systems, Palo Alto, CA) for optimization and then analyzed and 
compared to previous research and the originally planned case.  Details of these steps 
follow. 
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From Eclipse, anatomical structure data were exported in DICOM files.  These 
files were read in Computational Environment for Radiotherapy Research (CERR) via 
MATLAB (Mathworks, Natick, MA) to generate 3-dimensional images of the head and 
neck structures [23].  The CERR code has been adjusted to provide a constant cm-to-
pixel ratio of the 3D images.  Since the query plan cases will be generated from the 
match cases, 2D images of the BEV projection images at each of the 9 beam angles are 
acceptable for the match comparison.   
Each query case was compared to the remaining 102 database cases to determine 
the best matching cases.  In order to ensure a similar match PTV based on size, shape, 
and location, a mean squared error (SE) calculation was performed between the query 
patient and the match database’s 2D BEVs (180 and 260 degrees) to find the top 10 
geometrically matched PTVs.  The match BEVs for these angles were translated along 
the query image using a gradient descent of the least squared error measurement 
(Equation 1) in order to properly align the two images. 
 
In the above equation, the query is the target and each match is the moving 
image.  The I values represented here are the binary pixel intensities (1 in PTV and 0 
outside).  Figure 3 shows the BEV images before and after the shift is applied.  The shift 
(1) 
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allows for the match PTV to be properly aligned with the query for an optimal similarity 
metric. 
 
Figure 3: An unregistered query (green) BEV image at 180 degrees with the top 
PTV match (pink) on the left.  The shifted BEVs are now ready for the mutual 
information calculation (right). 
This initial alignment step reduced the amount of time and memory used later 
when computing mutual information.  For each of the paired angles, squared error was 
calculated and the sum  computed.  The case with the minimum summed squared error 
value corresponded to the case that has a PTV that is most similarly matched.   
To compute mutual information, two-dimensional BEV projection masks were 
created for each OAR.  The masks were images that assigned pixel values using the 
following numbering scheme such that each structure or PTV with its overlap had a 
unique number: 1 within the OAR, 2 within the PTV, 3 within the PTV/OAR overlap, 0 
elsewhere.   
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Figure 4: Example of BEV projection of overlap PTV with each OAR (light 
blue = OAR, red = OAR overlap with PTV, dark blue = outside of OAR) 
From the top 10 potential PTV matches, a mutual information similarity with the 
query and “match” for each OAR can begin.  The metric used for this was the summed 
mutual information of the overlap between the potential match and the query for each of 
the 9 projection angles.  This mutual information between the query and each potential 
match was calculated by the following equation. 
 
In the above equation, A is the query and B is the match, iA is the intensity level 
of image A and iB is the intensity level of image B, and PA and PB are probabilities of iA 
and iB occurring in images A and B respectively.  PAB shows the joint probability that the 
(2) 
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intensity of A, iA, will be present in the same pixel in B as iB. Mutual information was 
calculated and the potential match shifted over the query image along a gradient of 
steepest descent until the mutual information value is maximized.  This assured that the 
two images were aligned in the best way possible.  Of the 10 potential match cases, the 
case with the highest summed mutual information metric over all beam angles was 
designated to have the most geometrical similarity for a specific OAR of the query 
patient.  This process was performed for each OAR, generating 6 top match cases, one 
for each OAR.  The hypothesis was that finding a top match for each individual OAR 
would provide more accurate matches with better-fitting dose distributions for each 
OAR in question.   
2.3 Constraint Calculation and Priority/ Beam Angle Generation 
Prior KBRT work in prostate cases imported deformed beam fluences from the 
match case (deformed to suit the PTV/OAR geometry of the query case) in addition to 
the dose-volume constraints from the single top match to optimize the dose distribution 
in the query case [15, 24].  Since HNC cases are extremely variable in size and location, 
this method could not be used to optimize the query case.   
To generate better-suited constraints for the query case, the match case dose 
distribution for each OAR and target was warped to conform to the corresponding 
shapes of the OAR in the query case [21].  This dose warping was performed by 
mapping doses in concentric shells of equal thickness surrounding the match target 
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volume onto the concentric shells surrounding the query target volume.  The figure 
below represents the shell method of warping the dose.   
 
Figure 5: Doses in concentric shells of equal thickness surrounding the match 
target mapped onto concentric shells surrounding the query target volume 
 
Figure 5 shows the scenario in which the query OAR extends farther away from 
the target than the match case.  In the opposite situation of the match OAR extending 
farther away from the target than the query OAR, the match shells were scaled down to 
create smaller query shells.  The shells were scaled in proportion to the maximum 
extension of the query OAR from the target surface to the maximum extension of the 
match OAR from the target surface.  This was done to cause a steeper OAR dose falloff, 
eventually generating tighter constraints.  
Unlike prior HNC KBRT work where a single match using a composite of all 
OARs and the PTV to generate the dose-volume constraints (Version 1), the constraints 
were generated for each OAR based on its individual top match.  In order to produce 
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optimal query dose-volume constraints with optimal OAR sparing, the query dose-
volume constraints were set to the minimum from either: (a) the warped component 
plan dose distribution or (b) the warped total plan dose distribution (primary and boost) 
scaled in proportion to the ratio of the component plan to the total prescription dose. 
With the query dose distribution generated for each OAR, a hypothetical Dose-
Volume Histogram (DVH) plot was created in MATLAB.  For the larynx, oral cavity, left 
and right parotids, the absolute dose in cGy was extracted for the doses at 40% and 60% 
volume.  For both the brainstem and spinal cord +5mm, the max dose was extracted at 
1% volume.  These values correspond to the dose-volume constraints put into the IMRT 
optimization process.   
Since this method combines the different matches from each of the OARs, a 
single, overall context must be used in order to produce a plan that is consistent for the 
anatomy of the single query patient.  Both the priorities weightings for each constraint 
and the beam angles were extracted from the top match of the ipsilateral parotid (i.e., the 
parotid on the side where the tumor is primarily located).  This allows for consistent 
context instead of having 6 match cases mixed together.  Due to increased OAR plan 
quality, a PTV priority of 120 was selected to achieve better homogeneity of the PTV. 
2.4 Treatment Plan Generation and Optimization 
Using the query beam angles, dose-volume constraints, and priorities, a query 
treatment plan optimization was run in Eclipse until the objective function reached an 
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asymptote.  There was no user intervention of manually modifying the constraints 
during the optimization process. 
This research assumes contoured CT data has already been provided by the 
physician.  With the appropriate PTV target selected (primary or boost), a static plan 
was created on a Varian 21EX Linear accelerator with an energy of 6MV.   
 
Figure 6: Duke’s Varian 21EX Clinac 
Using the beam angles generated, new fields were created at the designated 
angles.  For each field, the collimator is fit to the structure with a 1 cm margin added.  
For all angles entering the patient posteriorly, the jaws were physically adjusted such 
that the beam did not penetrate the shoulders and impart extra dose through lung and 
healthy tissue.   
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Figure 7: Adjusting collimator jaws for posterior angles 
Once the beams and prescription dose were set, the optimization setup was 
begun.  Anisotropic Analytical Algorithm (AAA) is a pencil beam superposition 
convolution method used in Eclipse for dose calculations.  The jaws were fixed for 
posterior and lateral entry beams to reduce dose to the lungs and shoulders.  The dose-
volume constraints and priorities generated in MATLAB were entered into the 
optimization window.  We then allowed this optimization to run for 100 iterations or 
until the objective function reached an asymptote in order to ensure consistency and 
allow the minimization of the total objective function to be complete.   
 Once the optimization was complete, a fluence map was generated for each 
field.  The MU’s were calculated for each beam and then multi-leaf collimator (MLC) leaf 
motion was calculated for each field using the standard sliding window technique.  The 
dose-volume was then calculated and normalized such that 100% of the dose covered 
95% of the volume. 
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Figure 8: Patient with modulated fluence from beam at 140 degrees. The 
collimator jaws have been fixed above the shoulders 
For any additional boost plans, this process was repeated.  Dose-volume 
histograms were created in Eclipse for each plan.  For each plan (primary or boost), the 
PTV was selected for analysis of the homogeneity index (HI) and sigma index (SI).  In 
order to analyze the total dose delivered to each OAR in a composite DVH, a plan sum 
was created from the primary and any additional boost plans.   
2.5 Plan Evaluation and Analysis  
In order to provide an accurate comparison of MC-KBRT to each of the other 
methods (originally planned method and Version 1), they were compared side by side.  
The cases were separated into unilateral and bilateral cases in order to give an accurate 
comparison.  The contralateral parotid glands in unilateral cases were significantly 
spared compared to bilateral cases and this would skew the results.  Values for the OAR 
mean and median doses (larynx, oral cavity, parotids) or maximum doses (cord+5mm or 
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stem) were analyzed.  The parotid glands were characterized as either ipsilateral or 
contralateral.   
 
Figure 9: Ipsilateral Right Unilateral Parotid. 
Finally, the PTV was analyzed based on its maximum dose percentage, 
Homogeneity Index (HI), and Sigma Index (S-Index).  For both the OARs and the PTV, 
the maximum dose was defined as the dose to the highest 1% volume. 
The coverage of the PTV is the most significant criterion when first looking at 
HNC cases and then OAR sparing comes into play.  The PTV of the manually planned 
case, Version 1, and MC-KBRT were compared by evaluating the Homogeneity Index 
and the Sigma Index for each plan.  HI measures the steepness of the slope of the PTV 
DVH while the S-Index measures the deviation from the mean PTV dose [25].                 
%100*982
pD
DD
HI
−
=   (3)   
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In the HI equation, D2 and D98 represent doses to the highest 2% and 98% PTV volume, 
respectively, and Dp is the prescription dose 
∑ −=
total
i
meaniindex V
v
DDS *)( 2  
In the S-Index equation, Di is the dose within the volume vi, Dmean is the average dose in 
the PTV, and Vtotal is the total volume of the PTV.  HI and S-Index values were obtained 
for each plan PTV (primary/boost). 
Values for the median dose, mean dose, maximum dose, HI and S-Index were 
averaged for each method. An HI value below 15 was clinically acceptable along with a 
PTV maximum dose below 115% for both the primary and boost plans.   The PTV 
metrics were compared based on the individual plans (primary or boost) and the OAR 
metrics were compared based on the sum of the primary and boost plans (15/17 
unilateral cases had both primary and boost plans; all bilateral cases had both primary 
and boost plans).  The non-parametric Wilcoxon signed rank test was performed to 
determine statistical significance in the OAR and PTV dose difference between: (a) 
Original and Version 1; (b) Original and MC-KBRT; and (c) Version 1 and MC-KBRT 
[26]. 
 (4)   
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3. Results 
3.1 PTV and OAR Analysis 
 Tables 1 and 2 contain the average max dose percentage, HI, and S-Index along 
with the p-values for both the primary and boost cases of the 17 unilateral and 23 
bilateral cases, respectively.  For pair-wise comparisons (rightmost 3 columns), gray 
shading indicates the 1st listed method is better.  Bold facing indicates a p-value below 
0.05.  Gray shading indicates better PTV coverage in boost plans from MC-KBRT (MC) 
when compared to both the original (Orig) plan and Version 1 (V1) in columns 6 and 7, 
respectively.  Although the values for the primary max dose percentage, HI, and S-Index 
are significantly worse in MC-KBRT compared to the original plan for both unilateral 
and bilateral, the percent difference is clinically small.  The boost PTV for unilateral 
cases using MC-KBRT showed significant improvement over the originally planned 
cases, but still did not show a clinically significant difference. 
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Table 1: Max Dose Percent, Homogeneity Index, and S-Index averages and p-
values of 17 unilateral cases  
Unilateral 
Cases     P-values  
OAR 
Metric Original Version 1 MC-KBRT 
V1 - 
Orig 
MC - 
Orig 
MC - 
V1 
Primary 
Max 
Dose % 
107.91 ± 2.40 109.95 ± 2.94 109.14 ± 1.19 0.04 0.02 0.27 
Boost 
Max 
Dose % 
109.51 ± 2.07 107.78 ± 1.66 107.23 ± 1.20 0.06 <0.01 0.05 
Primary 
HI 9.65 ± 2.62 12.47 ± 7.45 9.95 ± 1.32 0.08 0.33 0.07 
Boost HI 11.05 ± 2.63 8.44 ± 1.59 7.65 ± 2.30 <0.01 <0.01 0.32 
Primary        
S-Index 1.05 ± 0.02 1.07 ± 0.03 1.06 ± 0.01 0.06 0.19 0.15 
Boost          
S-Index 1.01 ± 0.05 0.99 ± 0.05 0.99 ± 0.05 <0.01 <0.01 0.56 
 
Table 2: Max Dose Percent, Homogeneity Index, and S-Index averages and p-
values of 23 bilateral cases  
Bilateral 
Cases         P-values   
OAR 
Metric Original Version 1 MC-KBRT 
V1 - 
Orig 
MC - 
Orig 
MC - 
V1 
Primary 
Max 
Dose % 
109.48 ± 1.54 113.22 ± 3.98 113.07 ± 2.34 <0.01 <0.01 0.57 
Boost 
Max 
Dose % 
108.65 ± 2.26 108.48 ± 1.77 108.04 ± 1.73 0.68 0.26 0.08 
Primary 
HI 10.71 ± 2.05 14.11 ± 3.75 13.99 ± 2.51 <0.01 <0.01 0.83 
Boost HI 10.00 ± 2.97 9.46 ± 2.06 9.37 ± 3.06 0.41 0.16 0.24 
Primary        
S-Index 1.07 ± 0.02 1.10 ± 0.04 1.09 ± 0.02 <0.01 <0.01 0.79 
Boost          
S-Index 1.04 ± 0.03 1.04 ± 0.02 1.03 ± 0.02 0.42 0.06 0.10 
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The OARs were analyzed in a similar fashion of comparing the absolute dose in 
gray and computing p-values based on the dose differences for unilateral and bilateral 
cases.  Tables 3 and 4 contain the average dose values and the p-values for the dose 
differences for the 17 unilateral cases and the 23 bilateral cases, respectively.  Gray 
shading indicates better dose sparing in MC-KBRT (MC) when compared to either the 
original plan (Orig) or version 1 (V1) in columns 6 and 7, respectively.  Compared to the 
original, clinically approved treatment plan, gray shading in columns 5 and 6 ("Orig-V1" 
and "Orig-MC") indicates that both version 1 and the latest MC KBRT plans provided 
better dose sparing, albeit at the cost of increased dose for contralateral parotid that was 
not clinically significant.   
In unilateral cases, MC-KBRT had reduced dose compared to the original for all 
OARs with the exception of the contralateral parotid.  The contralateral parotid gland 
dose increased (2.98 ± 0.97 Gy to 4.12 ± 1.43 Gy median dose) and was below the 5 Gy 
threshold for all unilateral cases.  The oral cavity dose was significantly reduced in MC-
KBRT plans compared to the originals (22.82 ± 7.61 Gy to 19.69 ± 8.27 Gy median dose).  
Of the 17 unilateral cases, this dose reduction is clinically significant in preventing 
toxicity (Below the 25-30 Gy median dose threshold) in 3/17 cases.  Median doses of 
these plans are 32.55 Gy to 28.06 Gy, 30.46 Gy to 21.53 Gy, and 30.96 Gy to 26.09 Gy.  
Non-significant dose reduction to the ipsilateral parotid gland (mean and median), 
larynx (mean and median), brainstem (maximum), and cord+5mm (maximum) was 
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achieved in MC-KBRT compared to the original.  Doses to the contralateral parotid 
gland (mean and median) and brainstem (maximum) were reduced compared to 
Version 1, but were not significant. 
In bilateral cases, MC-KBRT had reduced dose to all of the OARs with the 
exception of the contralateral parotid when looking at the original plans.  The 
contralateral parotid gland median dose increased from 14.34 ± 3.38 Gy to 18.36 ± 7.32 
Gy which is below the 24 Gy clinically acceptable threshold.  The ipsilateral parotid 
gland median dose was significantly reduced from an average of 32.60 ± 15.5 to 21.71 ± 
7.32 Gy.  This proved to be clinically significant (Lowering the dose below the threshold 
of 24 Gy) in 8/23 cases.  Of these cases, the median dose values were reduced from 31.50 
Gy to 17.26 Gy, 39.59 Gy to 15.09 Gy, 24.66 Gy to 21.78 Gy, 45.15 Gy to 17.41 Gy, 39.86 
Gy to 23.52 Gy, 40.79 Gy to 13.91 Gy, 41.88 Gy to 18.02 Gy, and 41.87 Gy to 20.29 Gy.  
Lowering the median parotid gland dose reduces the chance of xerostomia.  MC-KBRT 
was also able to significantly reduce the median dose of the larynx from 25.81 ± 11.37 Gy 
to 22.85 ± 8.85 Gy.  This is clinically significant in 4/23 cases in which the threshold is 
reduced below the 24 Gy threshold.  Of these cases, the larynx median dose is reduced 
from 25.93 Gy to 22.95 Gy, 30.68 Gy to 21.97 Gy, 27.73 Gy to 23.36 Gy, and 26.28 Gy to 
16.38 Gy.  In addition to the ipsilateral parotid gland and larynx median doses being 
lowered, the MC-KBRT method also significantly improved the dose sparing to the oral 
cavity compared to the original plans, reducing the median dose from 30.76 ± Gy to 
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25.53 ± Gy.  In 4/23 cases, the median dose was reduced to below the 24 Gy threshold.  
These cases had reduction from 30.64 Gy to 22.19 Gy, 25.14 Gy to 22.82 Gy, 32.44 Gy to 
19.42 Gy, 36.21 Gy to 24.08 Gy, and 25.57 Gy to 22.76 Gy.  Compared to the original, 
dose reduction was also achieved in the brainstem and spinal cord but did not show 
clinical significance.  When MC-KBRT was compared to Version 1, non-significant dose 
reduction to all OARs except the contralateral parotid was achieved. 
 
Table 3: Absolute dose averages and p-values of 17 unilateral cases  
Unilateral 
Cases  
Absolute 
Dose (Gy)   P-values  
OAR Metric Original Version 1 MC-KBRT V1 - Orig 
MC - 
Orig 
MC – 
V1 
Ipsilateral 
Parotid 
Mean 
35.40 ± 10.40 33.43 ± 7.05 33.60 ± 8.52 0.52 0.23 1.00 
Ipsilateral 
Parotid 
Median 
31.29 ± 15.97 26.71 ± 11.04 27.49 ± 11.83 0.25 0.21 0.85 
Contralateral 
Parotid 
Mean 
3.34 ± 1.41 6.15 ± 2.60 5.45 ± 1.99 <0.01 <0.01 0.16 
Contralateral 
Parotid 
Median 
2.98 ± 0.97 4.53 ± 1.86 4.12 ± 1.44 <0.01 <0.01 0.27 
Larynx 
Mean 18.31 ± 6.77 17.21 ± 5.70 17.32 ± 9.88 0.23 0.08 0.23 
Larynx 
Median 14.27 ± 5.54 13.57 ± 4.91 13.81 ± 10.01 0.50 0.10 0.26 
Oral Cavity 
Mean 26.81 ± 8.28 22.87 ± 8.23 24.89 ± 9.44 0.03 0.03 0.06 
Oral Cavity 
Median 22.82 ± 7.61 17.27 ± 7.57 19.69 ± 8.27 0.02 0.01 0.06 
Brainstem 
Maximum 16.95 ± 11.77 15.73 ± 11.60 15.51 ± 11.93 0.33 0.33 0.98 
Cord+5mm 
Maximum 31.48 ± 7.46 28.55 ± 6.06 28.93 ± 6.03 0.06 0.14 0.65 
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Table 4:  Absolute dose averages and p-values for 23 bilateral cases  
Bilateral 
Cases  
Absolute 
Dose (Gy)   P-values  
OAR Metric Original Version 1 MC-KBRT V1 - Orig 
MC - 
Orig 
MC – 
V1 
Ipsilateral 
Parotid 
Mean 
34.55 ± 12.43 32.32 ± 7.11 29.86 ± 8.36 0.09 0.01 0.21 
Ipsilateral 
Parotid 
Median 
32.60 ± 15.49 24.40 ± 8.63 21.71 ± 9.53 <0.01 <0.01 0.26 
Contralateral 
Parotid 
Mean 
20.56 ± 4.60 23.81 ± 6.43 24.81 ± 6.62 0.01 <0.01 0.16 
Contralateral 
Parotid 
Median 
14.34 ± 3.38 16.70 ± 6.21 18.36 ± 7.32 0.14 <0.01 0.09 
Larynx 
Mean 28.29 ± 10.45 28.93 ± 9.55 26.11 ± 8.16 0.72 0.03 0.18 
Larynx 
Median 25.81 ± 11.37 25.04 ± 9.75 22.85 ± 8.85 0.31 <0.01 0.48 
Oral Cavity 
Mean 34.72 ± 10.51 34.10 ± 8.88 31.15 ± 10.29 0.04 <0.01 0.14 
Oral Cavity 
Median 30.76 ± 12.31 28.23 ± 10.16 25.53 ± 10.29 0.03 <0.01 0.50 
Brainstem 
Maximum 18.84 ± 10.21 17.89 ± 8.09 16.18 ± 6.86 0.41 0.06 0.07 
Cord+5mm 
Maximum 35.28 ± 5.49 33.27 ± 5.71 33.00 ± 5.07 0.10 0.11 0.95 
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3.2 Case-wise Analysis 
When analyzing HNC cases, it is helpful to evaluate all of the cases and 
investigate how many OARs perform better or worse than the original and Version 1 
plans.  Tables 5 and 6 compare the OARs for the 17 unilateral and 23 bilateral cases 
respectively, grouped according to the number of OARs (out of 6) for which the plans 
were either better (lower dose than the original plan by more than 5%) or comparable 
(the percent difference from the original plan is within +/- 5%).  Table 5 shows the MC-
KBRT plan was comparable or better to the original plan in 11/17 cases for ≥ 4OARs and 
in 15/17 cases for at least half of the OARs in the unilateral cases.  For bilateral cases in 
Table 6, 14/23 cases for ≥ 4 OARs and 20/23 cases for more than half of the OARs in MC-
KBRT were better or comparable to the original.  When compared to Version 1, 9/17 
unilateral cases and 13/23 bilateral cases were better or comparable for ≥ 4OARs with 
12/17 unilateral cases and 20/23 bilateral cases being better or comparable for more than 
half of the OARs. 
 
Table 5:  Number of unilateral cases (% of cases) for which OARs were better 
spared in the MC-KBRT plan compared to both the original plan and Version 1 
Number of OARs that were better or 
comparable (out of 6 OARs) 
Original - 
Version 1 
Original - 
MC-KBRT 
Version 1 - 
MC-KBRT 
6 OARs 0    (0%)  0    (0%)  0    (0%)  
≥ 5 OARs 0    (0%)  3  (18%) 2  (12%) 
≥ 4 OARs 9  (53%) 11  (65%) 9  (53%) 
≥ 3 OARs 14  (82%) 15  (88%) 12  (71%) 
< 3 OARs 3  (18%) 2  (12%) 5  (29%) 
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Table 6: Number of bilateral cases (% of cases) for which OARs were better 
spared in the MC-KBRT plan compared to both the original plan and Version 1 
Number of OARs that were better or 
comparable (out of 6 OARs) 
Original - 
Version 1 
Original - 
MC-KBRT 
Version 1 - 
MC-KBRT 
6 OARs 3  (13%) 1    (6%) 1    (6%) 
≥ 5 OARs 6  (26%) 5  (22%) 7  (30%) 
≥ 4 OARs 13  (57%) 14  (61%) 13  (57%) 
≥ 3 OARs 20  (87%) 20  (87%) 20  (87%) 
< 3 OARs 3  (13%) 3  (13%) 3  (13%) 
 
In addition to analyzing the total number of OARs that have better dose sparing 
in each method, we compiled the number of specific OARs and PTVs.  With the 
exception of the contralateral parotid gland, all of the OARs had better dose sparing in 
at least half of the cases (>7 unilateral and >11 bilateral) when the MC-KBRT plan was 
compared to the original plan as seen in Tables 7 and 8.  Dose sparing in more than half 
of the OARs were achieved when MC-KBRT was compared to Version 1 for both 
unilateral and bilateral cases with the exception from the unilateral oral cavity.  The 
multi-case KBRT method can achieve better OAR dose reduction in more than half of the 
cases when compared to Version 1.  
Tables 7 and 8 also show an analysis of the PTVs of both the primary and boost 
cases.  When the MC-KBRT was compared to the original plan (Orig), worse primary 
PTV coverage was seen (Only 7/17 unilateral and 3/23 bilateral PTVs were better) 
although the boost PTV coverage was better in more than half of the cases.  When 
unilateral cases of MC-KBRT (MC) were compared to Version 1 (V1) in column 4 of 
Tables 7, more than half of the unilateral primary PTVs and 12/15 boost PTVs were 
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better.  MC-KBRT was able to achieve better PTV coverage than Version 1 in unilateral 
cases; however the dosimetric difference is small.  Doses to the contralateral parotid 
gland (median and mean) and brainstem (maximum) were reduced compared to 
Version 1 but were not significant.  In the bilateral cases in Table 8, primary PTV 
coverage was evenly split between MC-KBRT and Version 1.  Boost PTV coverage was 
slightly better in MC-KBRT than Version 1, showing 16/23 cases with improved PTVs. 
 
Table 7: OAR/PTV – specific comparison for 17 unilateral cases between 
Version 1, MC-KBRT, and the original plan (Values represent the number of cases in 
the 2nd method that have lower doses than the 1st method) 
Structure Orig – V1 Orig - MC V1 – MC 
Ipsilateral Parotid Gland (out of 15) 9  (60%) 10  (67%) 9  (60%) 
Contralateral Parotid Gland 2  (12%) 3  (18%) 10  (59%) 
Larynx (out of 16) 9  (56%) 12  (75%) 14  (88%) 
Oral Cavity 13  (76%) 14  (82%) 6  (35%) 
Spinal Cord 13  (76%) 13  (76%) 10  (59%) 
Brainstem 10  (59%) 11  (65%) 9  (53%) 
Primary PTV 5  (29%) 7  (41%) 12  (71%) 
Boost PTV (out of 15) 13  (87%) 12  (80%) 12  (80%) 
 
Table 8: OAR/PTV – specific comparison for 23 bilateral cases between 
Version 1, MC-KBRT, and the original plan (Values represent the number of cases in 
the 2nd method that have lower doses than the 1st method) 
Structure Orig - V1 Orig - MC V1 – MC 
Ipsilateral Parotid Gland  19  (83%) 16  (70%) 14  (61%) 
Contralateral Parotid Gland 7  (30%) 4  (17%) 11  (48%) 
Larynx (out of 21) 13  (62%) 20  (95%) 14  (67%) 
Oral Cavity 16  (70%) 19  (83%) 14  (61%) 
Spinal Cord 17  (74%) 16  (80%) 15  (65%) 
Brainstem (out of 22) 12  (55%) 14  (64%) 18  (82%) 
Primary PTV  2    (9%) 3  (13%) 13  (57%) 
Boost PTV 14  (61%) 17  (74%) 16  (80%) 
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Figure 10 shows the DVHs of an ipsilateral left bilateral case (Case 4).  When MC-
KBRT is compared to both the original and Version 1, 5 OARs are comparable.  Only the 
contralateral parotid is failing in both cases.  When the PTVs are compared, MC-KBRT’s 
primary PTV performs worse than the original and Version 1, but the HI is still below 
15.  The boost PTV was better in MC-KBRT compared to both methods. 
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Bilateral Case 4 
       Original Plan ( __ ) vs. MC-KBRT ( …. )          Version 1 (  __  ) vs. MC-KBRT ( …. ) 
 
 
  
 
                                                                                                     
 
 
 
 
 
  
 
 
  
 
Figure 10: DVH of case 4 for OAR (first row), Primary PTV (middle row), and 
Boost PTV (bottom row) for MC-KBRT compared to both the Original plan (left 
column) and Version 1 (right column).  
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Figure 11 shows the DVHs for an ipsilateral right unilateral case (Case 89).  
When MC-KBRT is compared to the Original, 4 OARs are comparable.  Only the 
contralateral left parotid gland and brainstem are worse than the original plan.  Similar 
PTV coverage is achieved.  When MC-KBRT is compared to Version 1, 5 OARs are 
worse.  Only the ipsilateral parotid is better in MC-KBRT.  As is visible in the primary 
PTV, having good PTV coverage can make OARs harder to spare.  This is a case in 
which MC-KBRT was better than the original, but Version 1 outperformed MC-KBRT. 
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Unilateral Case 89 
         Original Plan ( __ ) vs. MC-KBRT ( …. )           Version 1 (  __  ) vs. MC-KBRT ( …. ) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: DVH of case 89 for OAR (first row), Primary PTV (middle row), and 
Boost PTV (bottom row) for MC-KBRT compared to both the Original plan (left 
column) and Version 1 (right column). 
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Figure 12 shows case 58 which is an ipsilateral left bilateral case (Case 58).  When 
MC-KBRT is compared to the original plan, of the 6 OARs only the spinal cord and the 
contralateral parotid were better.  From the DVHs, it is apparent that the dose 
differences are small but MC-KBRT did not spare the OARs as much.  Comparing MC-
KBRT to Version 1, all OARs except the ipsilateral parotid were better.  This is a case in 
which both MC-KBRT and Version 1 did not outperform the Original case, but MC-
KBRT was able to show superior quality to Version 1. 
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Bilateral Case 58 
       Original Plan ( __ ) vs. MC-KBRT ( …. )            Version 1 (  __  ) vs. MC-KBRT ( …. ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: DVH of case 58 for OAR (top row), Primary PTV (middle row), and 
Boost PTV (bottom row) for MC-KBRT compared to both the original plan (left 
column) and Version 1 (right column).
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4. Conclusion and Future Work 
4.1 Discussion 
Knowledge-based IMRT treatment planning is intended to generate consistent 
quality plans more quickly than manual planning while simultaneously removing the 
number of decisions to be made by the planner.  Other knowledge-based studies simply 
use the treatment parameters from the match case[15, 17, 18, 19].  This study uses dose 
warping to generate the constraints.  Current single-match knowledge-based treatment 
planning methods semi-automatically allow the user to create comparable plans.  The 
purpose of multi-case KBRT is to improve upon already existing KBRT methods.  By 
finding top geometric “matches” for individual OARs, better organ sparing should be 
achievable without deteriorating the target coverage.  The results of this study show that 
the MC-KBRT method generates quality HNC plans that are dosimetrically similar to 
both Version 1 and the original plans.   
In unilateral cases, MC- KBRT had reduced dose compared to the original for all 
OARs with the exception of the contralateral parotid gland.  Only the oral cavity was 
significantly spared in the MC-KBRT version.  It is more difficult to improve upon 
unilateral plans since the PTV is generally smaller and OARs are farther from the target.   
In bilateral cases, MC-KBRT showed greater OAR dose reduction than in the 
unilateral cases.  Due to the intricate geometry of bilateral cases, the plans are harder to 
create in an automated fashion.  The dose warping sets constraints that can spare the 
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OARs much more significantly.  When MC-KBRT was compared to Version 1, non-
significant dose reduction to all OARs except the contralateral parotid was achieved.  
Although there is some dosimetric improvement made by MC-KBRT compared to 
Version 1, the dose difference is small it is not clinically significant.  Analyzing more 
cases may make the dose difference significant for bilateral OARs but it still will not be 
clinically significant. 
In both the unilateral and bilateral cases, MC-KBRT did not outperform Version 
1 significantly.  This suggests there may be better ways to merge together disparate data 
from multiple cases in order to fully realize the potential of the improved overlap of 
PTV with individual OARs.  This is likely because the dose-warping strategy diminishes 
the disadvantages of picking from a single case, i.e., there is no significant advantage to 
selecting from multiple cases.  The dose warping appears to adequately adjust the dose 
to individual OARs, so choosing multiple match cases is not as important.  If MC-KBRT 
were compared to earlier attempts of Version 1 in which the treatment parameters were 
taken directly from a single match case, it is likely that the current method of multiple 
match cases would have performed better. 
  Manually planning a HNC IMRT case generally takes between 2-6 hours.  The 
single match KBRT method (Version 1) reduces this time to about 35 minutes per plan 
(primary or boost).  The new MC-KBRT method takes about 45 minutes per plan 
(primary or boost).  Since both Version 1 and MC-KBRT generate comparable plans 
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(both equally improved when compared to the original), it would seem there is no 
significant improvement in MC-KBRT since it is more time-consuming.  
4.2 Future Work 
This multi-case KBRT method utilizes 6 “match” OAR cases to generate a new 
query plan.  In order to have quality plans, an optimized database is required.  Current 
work is being performed to manually optimize the cases already in the knowledge 
database.  Some suboptimal plans in HNC cases are unavoidable in the clinic due to the 
complexity and close proximity of the OARs to the target.  With better match dose 
distributions, tighter query constraints can be calculated, producing better plans. 
In addition to optimizing the already existing database, increasing the size of the 
database to more than 103 patients would be helpful.  Since HNC target geometry is 
quite variable, having more potential match cases would allow for a better geometric 
match for each OAR.   
MC-KBRT IMRT treatment planning does not weight the constraints and 
priorities generated for individual OARs.  Since certain OARs such as the brainstem and 
contralateral parotid glands are more sensitive, investigation into weighting these 
warped constraints/priorities is in progress.  More uniform OAR sparing with better 
target coverage may be achievable. 
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4.3 Conclusions 
The results of 17 unilateral HNC plans show general dose reduction in most of 
the OARs while maintaining PTV coverage when compared to clinical manually 
planned cases.  The 23 bilateral HNC plans show significant improvement in all OARs 
but the contralateral parotid gland.  It is easier to improve the bilateral cases because the 
dose warping method imposes lower constraints to push down the OAR doses.   
When compared to single match KBRT (Version 1), there is no significant 
improvement.  Since the results are very similar but not significantly improved, the 
original KBRT method seems to be more efficient in both time saving and dose sparing.
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Appendix  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unilateral Patient Information 
  
 
   
# of cases Type of Cancer 
Primary Dose 
(Gy) 
Boost Dose 
(Gy) 
1 Left Parotid gland cancer 54 6 
1 Right Parotid Gland cancer 64 0 
1 Oral tongue cancer 50 20 
1 Recurring ethmoidal sinus cancer 60 6 
1 Bone and bone marrow cancer 44 16 
1 Lymph node cancer 50 10 
5 Left Tonsil cancer 50 20 
    50 10 
    50 10 
    44 26 
    44 16 
6 Right Tonsil cancer 60 0 
    46 24 
    44 26 
    44 26 
    44 26 
    44 26 
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Bilateral Patient Information 
  
    
# of cases Type of Cancer 
Primary Dose 
(Gy) 
Boost Dose 
(Gy) 
1 Glottis cancer 50 20 
1 Supraglottis cancer 44 26 
1 Lip cancer (vermillion border) 44 16 
1 Oropharyngeal cancer 44 26 
1 Right tonsil cancer 44 26 
1 Left tonsil cancer 46 24 
2 Nasopharyngeal cancer 44 26 
    44 26 
6 Lymph node cancer 50 20 
    44 26 
    44 26 
    44 26 
    44 26 
    44 26 
9 Base of tongue cancer 50 20 
    50 20 
    44 26 
    44 26 
    44 26 
    44 26 
    44 26 
    44 26 
    44 22 
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